RNAi Therapeutic ARC-AAT Induces Dose Dependent Reductions in Mutant AAT Protein of Greater than 95 Percent in Preclinical Studies Long Duration of Effect with AAT …
Alnylam and The Alpha-1 Project (TAP) Form Collaboration for Advancement of ALN-AAT, an RNAi Therapeutic in Development for the Treatment of Alpha-1 Antitrypsin (AAT) Deficiency-Associated Liver Disease
Alnylam Remains On Track to File Investigational New Drug (IND) Application in Mid-2015 June 19, 2015 Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and …